Eileen E. Ming, MPH, ScD
About
Eileen E. Ming holds graduate training in public health (MPH) and epidemiology (ScD) and works in pharmacoepidemiology, with a research focus on the real-world safety and effectiveness of medications. Her published work draws on large administrative claims and electronic medical records databases to study drug utilization patterns and cardiovascular outcomes in clinical practice populations.
Her peer-reviewed publications, appearing in journals such as Pharmacoepidemiology and Drug Safety, the Journal of Clinical Lipidology, and the Journal of Clinical Psychiatry, address topics including lipid-lowering therapies, statin safety and effectiveness, postmarketing observational study design, and the prevalence of binge eating disorder under evolving diagnostic criteria. One line of work examined concomitant statin and fibrate therapy for pharmacoepidemiology safety signals; another assessed rosuvastatin effectiveness across nearly 400,000 patients drawn from clinical practice data. Additional published work contributed to the rationale and design of postmarketing safety studies for saxagliptin.
This background in large-scale observational research and drug safety methodology positions Dr. Ming to provide analysis in matters involving pharmaceutical litigation, adverse event causation, epidemiological study design, and the interpretation of administrative health data.
Credentials
Publications
- Thiol-ene/oxidation tandem reaction under visible light photocatalysis: synthesis of alkyl sulfoxides.
- Estimating the Prevalence of Binge Eating Disorder in a Community Sample From the United States: Comparing DSM-IV-TR and DSM-5 Criteria.
- Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
- Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies.
- Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.
- Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
- Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice.
- Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases.
- Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings.
- The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
Request CV and rates
Tell us about your case and we'll connect you with Eileen E. Ming, MPH, ScD within two business days.
Other experts
Verified specialists available for your case.
